investors

MethylGene and Pharmion Expand Collaboration on Epigenetic Therapies

Monday, August 20th, 2007

MethylGene Inc. (TSX:MYG) and Pharmion Corporation (NASDAQ:PHRM) today announced a “research collaboration for the development of novel small molecule inhibitors targeting sirtuins, a separate and distinct class of histone deacetylase enzymes (Class 3 HDACs) implicated in cell survival and death.”
MethylGene and Pharmion’s Class I specific HDAC inhibitor, MGCD0103, has demonstrated efficacy in a number of [...]

SensiGen Secures Option for Licensing Lupus Biomarkers

Wednesday, July 11th, 2007

Ann Arbor, Michigan-based SensiGen LLC has acquired an option to license a set of epigenetic biomarkers for the early detection and monitoring of lupus from the University of Michigan. The technology consists of “a patented panel of proprietary biomarkers for epigenetic variations of genes uniquely associated with Lupus along with related research assays.
We previously covered [...]

Global Epigenomics Market to Reach $4.1 Billion by 2012

Friday, May 11th, 2007

“$4.1 Billion by 2012″ is the major finding of a market report on the global epigenomics market published by BCC Research. The report identified three key market segments that will be commercially important in the field of epigenomics in the next 5 years: research tools, cancer diagnostics, and cancer therapeutics.
There are three major highlights from [...]

Epigenetics Attracting Attention from Investors

Monday, March 12th, 2007

I’ve talked before about e-mails I commonly receive from consultants, investors, and others regarding investment ideas of companies that are poised to take advantage of the research being done in epigenetics. I thought I would share a recent example of one such e-mail:
Hello Trevor-
Congrats on getting this site up. I [...]

Potential Conflict of Interest at NIEHS

Wednesday, March 7th, 2007

The National Institutes of Environmental Health Sciences (NIEHS) is under fire. Effect Measure, a blog written anonymously by public health experts and practitioners, has written a critical review of David Schwartz’s two year term as director of the NIEHS:
Schwartz, like other Bush appointees, has a penchant for outsourcing public functions to private concerns, and under [...]

Nygaard Named New CEO of Epigenomics AG

Wednesday, January 17th, 2007

Epigenomics AG (Frankfurt: ECX) has appointed its new CEO: Geert Walther Nygaard, formerly managing director and member of the management board of pharmaceutical and diagnostics company Abbott GmbH & Co. KG.Nygaard started his career in Denmark, working for Diagnostics companies Beckman Instruments and Dako A/S in national and international positions. He joined Abbott in 1999 [...]